Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

NCT ID: NCT07272590

Last Updated: 2025-12-09

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 290 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-30
• Study Completion Date: 2031-08-31

Brief Summary

The goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant solid tumors. This study is divided into two phases: Phase Ib is the combined dose escalation phase, where dose escalation of QLC5513 combined with QL1706± platinum is conducted and RP2D is explored; In the Phase II tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLC5513 combined with QL1706± platinum-based treatment in patients with advanced or metastatic malignant solid tumors.

Conditions

Metastatic Solid Tumors

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: QLC5513+QL1706

Group Type: EXPERIMENTAL

QLC5513 IV infusion

Intervention Type: DRUG

Participants will receive QLC5513 16 mg/kg intravenously on Days1, Day 8 and Day 15 of 28-day cycles.

QL1706, IV infusion

Intervention Type: BIOLOGICAL

QL1706 5mg/kg intravenously on Day 1 of 21-day.

Arm B: QLC5513+QL1706+ platinum

Group Type: EXPERIMENTAL

QLC5513 IV infusion

Intervention Type: DRUG

Participants will receive QLC5513 16 mg/kg intravenously on Days1, Day 8 and Day 15 of 28-day cycles.

QL1706, IV infusion

Intervention Type: BIOLOGICAL

QL1706 5mg/kg intravenously on Day 1 of 21-day.

platinum, IV infusion

Intervention Type: DRUG

Cisplatin: 75 mg/m ² or carboplatin：AUC=5 mg/mL/min on Day 1 of 21-day.

Interventions

QLC5513 IV infusion

Participants will receive QLC5513 16 mg/kg intravenously on Days1, Day 8 and Day 15 of 28-day cycles.

Intervention Type: DRUG

QL1706, IV infusion

QL1706 5mg/kg intravenously on Day 1 of 21-day.

Intervention Type: BIOLOGICAL

platinum, IV infusion

Cisplatin: 75 mg/m ² or carboplatin：AUC=5 mg/mL/min on Day 1 of 21-day.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1.

2. Has adequate organ function.

3. The expected survival period is ≥3 months.

4. Based on the pathological report of the most recent biopsy or other pathological specimens, advanced or metastatic solid tumors confirmed by histology or cytology are not suitable for radical treatments such as surgery and radiotherapy.

5. According to the RECIST v1.1 evaluation criteria, the participants had at least one radiologically measurable lesion.

Exclusion Criteria

1. Prior treatment with TROP2-targeting agents, ADCs with topoisomerase 1 inhibitor (TOP1i) payloads, or other TOP1i drugs.

2. There was symptomatic central nervous system (CNS) metastasis, leptomeningeal metastasis or spinal cord compression caused by metastasis before the first use of the investigational product.

3. Active, uncontrolled bacterial, fungal or viral infections.

4. Radiotherapy with more than 25% of the bone marrow exposed within 4 weeks prior to the first use of the investigational drug; Local radiotherapy (excluding brain radiotherapy) was performed within two weeks before the first use of the investigational drug.

5. Subjects with a history of a second malignant tumor other than the target indication within 5 years prior to signing the informed consent (excluding cured basal cell skin cancer, superficial bladder cancer, carcinoma in situ of the breast, papillary thyroid carcinoma, etc.).

6. Prior to the first dose of the investigational product, all reversible toxicities from prior anti-tumor therapy (excluding alopecia and pigmentation) have not recovered to ≤ Grade 1 (as assessed by CTCAE v5.0), with the exception that peripheral neuropathy must have not recovered to ≤ Grade 2. History of irAEs from prior immune checkpoint inhibitor treatment that required permanent discontinuation of the immune checkpoint inhibitor.

7. Active autoimmune disease that has required systemic treatment in the past 2 years.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Zefei Jiang, Professor

Role: CONTACT

jzf_cscobc@csco.org.cn

86-010-66947175

Other Identifiers

QLC5513-201

Identifier Type: -

Identifier Source: org_study_id